Shares in big vaccine producers have slumped since Donald Trump asked Robert F. Kennedy (RFK) Jr. to lead the Department of Health and Human Services, says The New York Times. Kennedy, known for his “divisive” views on public health, including “scepticism” about vaccines (as well as pesticides and water fluoridation) is to lead “a huge department… whose regulations affect America’s food and medicine choices”.
How could RFK Jr impact the US healthcare industry?
Installing RFK Jr in an official administration role “may be difficult”, as his anti-vax views have been so extreme that they led to bans on YouTube and Instagram, says Robert Cyran on Breakingviews. That “might preclude confirmation even in a Republican-led Senate”.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
However, even if he only ends up serving as a senior advisor, it would still give him “plenty of scope to target the pharmaceutical and related industries”. While RFK has said in interviews that “he wouldn’t take away anyone’s vaccines”, he reportedly wants to remove product liability protection from vaccines, a step that might have a “similarly harmful effect”.
Whatever role Kennedy eventually plays, even his presence within the administration could “erode public trust” in vaccines, “put up roadblocks to the approval of new vaccines and prevent the CDC from recommending any vaccines that make it through the approval process”, says Morningstar’s Karen Andersen. This, in turn, could mean that certain US states could “waver” in support of broad mandates for childhood vaccines. Still, any reduction in projected US vaccine sales would not be “long-lasting”, and so this should not provide “a significant hit” to drug companies’ valuations.
The industry hopes that RFK’s influence may be cancelled out by other “smart people” advising Trump, say Ian Johnston and Oliver Barnes in the Financial Times. They could restrain RFK, while there may be increased benefits from the stockpiling of certain vaccines for defence purposes.
Vivek Ramaswamy, appointed alongside Elon Musk to oversee a state efficiency drive, has also been a big fan of reducing red tape in the drug approval process, accusing the FDA of erecting “unnecessary barriers to innovation”.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
What is the 25x retirement rule and does it work?The 25x retirement rule has been around for decades but many experts question if it is a suitable strategy
-
When is the self-assessment tax return deadline?If you are self-employed, rent out a property or earn income from savings or investments, you may need to complete a self-assessment tax return. We run through the deadlines you need to know about
-
Are wealthy whisky enthusiasts leaving Britain?Collectables Wealthy whisky enthusiasts are heading to tax-friendly countries such as Dubai, where there is more disposable income to spend on collectable luxuries like rare whisky.
-
'The rise and fall of Kodak is a lesson for the tech giants'Opinion The long decline of Kodak – a once-dominant company – shows why no business is safe from disruption, says Matthew Lynn
-
The financial crisis in UK universities – what can be done?UK universities are running out of cash and have begun to shed staff; bankruptcies look likely. What’s gone wrong, and what should be done about it?
-
8 of the best properties for sale with kitchen gardensThe best properties for sale with kitchen gardens – from a 17th-century timber-framed hall house in Norfolk, to an Arts & Crafts house in West Sussex designed by Charles Voysey with a garden by Gertrude Jekyll
-
'Governments are launching an assault on the independence of central banks'Opinion Say goodbye to the era of central bank orthodoxy and hello to the new era of central bank dependency, says Jeremy McKeown
-
Why investors can no longer trust traditional statistical indicatorsOpinion The statistical indicators and data investors have relied on for decades are no longer fit for purpose. It's time to move on, says Helen Thomas
-
Investors rediscover the virtue of value investing over growthGrowth investing, betting on rapidly expanding companies, has proved successful since 2008. But now the other main investment style seems to be coming back into fashion.
-
8 of the best properties for sale with shooting estatesThe best properties for sale with shooting estates – from an estate in a designated Dark Sky area in Ayrshire, Scotland, to a hunting estate in Tuscany with a wild boar, mouflon, deer and hare shoot
